Key Details
Price
$0.76Last Dividend
$0.10TTM Dividend Yield
13.20%Annual ROE
-38.76%Beta
0.49Events Calendar
Next earnings date:
Mar 13, 2025Recent quarterly earnings:
Dec 16, 2024Recent annual earnings:
Oct 14, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 15, 2024Next split:
N/ARecent split:
Oct 21, 2004Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Enzo Biochem has announced a loss for the first quarter of fiscal 2025, along with a decrease in revenue in various regions, due to difficulties in the life sciences tools market.
Enzo Biochem reports a first-quarter fiscal 2025 quarterly loss and revenue drop across regions amid challenges in the life sciences tools market.
FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024.
Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock.
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks.
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
FAQ
- What is the primary business of Enzo Biochem?
- What is the ticker symbol for Enzo Biochem?
- Does Enzo Biochem pay dividends?
- What sector is Enzo Biochem in?
- What industry is Enzo Biochem in?
- What country is Enzo Biochem based in?
- When did Enzo Biochem go public?
- Is Enzo Biochem in the S&P 500?
- Is Enzo Biochem in the NASDAQ 100?
- Is Enzo Biochem in the Dow Jones?
- When was Enzo Biochem's last earnings report?
- When does Enzo Biochem report earnings?